Literature DB >> 3987171

Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.

J G Wagner.   

Abstract

Average steady-state propranolol plasma concentration (Css) were calculated from published steady-state propranolol clearance data for dose rates (Ro) of 40, 80, 160, 240, and 320 mg/ day in divided doses every 6 hours. The Css-Ro data for each of four subjects were fit essentially perfectly by the equation: Css = KmRo/ (Vm-Ro). Very similar Vm and Km values were obtained with the Vmi and Kmi values for four parallel Michaelis-Menten pathways of propranolol metabolism. It is shown by use of the mean Vm and Km values that the propranolol input rate profoundly affects its bioavailability, which is expected for a first-pass drug that follows Michaelis-Menten elimination kinetics after oral dosing. This most likely explains the poor bioavailability of propranolol after a sustained-release formulation. The decreased bioavailability of propranolol when the number of subdivisions of the daily dose is increased is also explained.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987171     DOI: 10.1038/clpt.1985.76

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

3.  Mechanisms and variations in the food effect on propranolol bioavailability.

Authors:  H Liedholm; E Wåhlin-Boll; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

5.  Pharmacokinetic and pharmacodynamic comparison of two doses of long acting propranolol (80 and 160 mg) in healthy subjects.

Authors:  B Flouvat; I Berlin; A Cournot; D Robinet; J Duchier; H Sarmini; A Rossi
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

6.  The assessment of bioavailability in the presence of nonlinear elimination.

Authors:  S D Hall; C B McAllister; G R Wilkinson
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

Review 7.  Theophylline. Pooled Michaelis-Menten parameters (Vmax and Km) and implications.

Authors:  J G Wagner
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 8.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

9.  Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers.

Authors:  J Vanakoski; T Seppälä
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state.

Authors:  R L Lalonde; J A Pieper; R J Straka; M B Bottorff; D M Mirvis
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.